New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 5, 2012
10:01 EDTWDAY, RGLS, ICPT, AMBA, SSTK, MUSA, CHTR, ADT, BSMX, KYTH, ANFIOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ADT Corp. (ADT) initiated with a Buy at Citigroup... Ambarella (AMBA) initiated with a Buy at Deutsche Bank... Amira Nature Foods (ANFI) initiated with a Buy at Deutsche Bank... Charter (CHTR) initiated with an Underweight at Barclays... Intercept Pharmaceuticals (ICPT) initiated with a Buy at Needham... Kythera Biopharmaceuticals (KYTH) initiated with a Neutral at Goldman... Metals USA (MUSA) initiated with an Outperform at Wells Fargo... Regulus Therapeutics (RGLS) initiated with a Buy at Needham... Santander Mexico (BSMX) initiated with a Buy at Citigroup... Shutterstock (SSTK) initiated with a Buy at Jefferies... Workday (WDAY) initiated with a Buy at Canaccord.
News For ADT;AMBA;ANFI;CHTR;ICPT;KYTH;MUSA;RGLS;BSMX;SSTK;WDAY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 13, 2015
08:24 EDTICPTDeutsche Bank pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
07:22 EDTCHTRWave of media M&A may be on the way, WSJ says
Subscribe for More Information
06:07 EDTICPTIntercept announces several presentations evaluating OCA
Subscribe for More Information
April 12, 2015
15:07 EDTADTADT, Post, three other spinoffs could go higher, Barron's says
Citizens Financial (CFG), KLX (KLXI), ADT (ADT), Post Holdings (POST), and Rouse Properties (RSE) are spinoffs that look attractive, Barron's contends in a feature article. Reference Link
April 11, 2015
14:46 EDTMUSAMurphy USA to host analyst day
Analyst Day to be held on April 16 at 9:30 am. Webcast Link
April 10, 2015
11:47 EDTKYTHKYTHERA rallies after BofA/Merrill reinstates with Buy, $66 target
BofA/Merrill this morning reinstated coverage of KYTHERA Biopharmaceuticals with a Buy rating and $66 price target. The firm believes the company's ATX-101 has "significant" sales potential for the treatment of double chin. If approved, ATX-101 will be the first drug indicated for double chin, BofA/Merrill noted, and the first minimally invasive option for patients to reduce chin size. Shares of KYTHERA are up $1.87 to $48.87 in midday trading.
10:00 EDTADTOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:30 EDTWDAYWorkday to hold financial analyst day
Financial Analyst Day to be held in San Francisco on April 15 at 12 pm. Webcast Link
06:06 EDTADTADT Corp. downgraded to Neutral from Buy at Citigroup
Subscribe for More Information
April 9, 2015
08:20 EDTICPTWedbush reiterates $493/share acquisition value for Intercept
Subscribe for More Information
08:10 EDTRGLSRegulus to present positive results for HCV candidate RG-101
Regulus announced multiple presentations related to RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 for the treatment of chronic Hepatitis C Virus infection scheduled for presentation at The International Liver Congress.The new clinical data demonstrates that RG-101 shows dose responsive pharmacodynamics with maximal changes at 2 mg/kg in healthy volunteers and no drug-drug interactions observed when administered in combination with the direct acting anti-viral drug simeprevir. Additional data supports the evaluation of RG-101 in human clinical trials. Following subcutaneous administration, rapid absorption and clearance of RG-101 was observed in plasma with rapid uptake and efficient conversion to unconjugated oligonucleotide in the liver and reduced concentrations in kidney.
07:44 EDTCHTRComcast risks overblown, shares offer attractive upside, says Jefferies
Subscribe for More Information
April 8, 2015
19:46 EDTRGLSOn The Fly: After Hours Movers
UP AFTER EARNINGS: Apogee (APOG), up 6.4%... Pier 1 Imports (PIR), up 4.4%. ALSO HIGHER: Inovio Pharmaceuticals (INO), up 5.6% after being selected by DARPA to lead $45M Ebola prevention program. DOWN AFTER EARNINGS: Alcoa (AA), down 3.5%... Bed Bath & Beyond (BBBY), down 3.5%. ALSO LOWER: Zynga (ZNGA), down 10.3% after announcing CEO transition... Memorial Production (MEMP), down 2.9% after filing to sell 4.6M common units owned by MRD Holdco... Regulus (RGLS), down 2.2% after filing to sell 3.3M shares for Isis Pharmaceuticals.
16:11 EDTRGLSRegulus files to sell 3.3M shares for Isis Pharmaceuticals
Subscribe for More Information
09:20 EDTRGLSOn The Fly: Pre-market Movers
Subscribe for More Information
09:05 EDTWDAYWorkday expands New York headquarters within Empire State Realty portfolio
Workday (WDAY) has expanded its New York headquarters within the Empire State Realty (ESRT) portfolio, relocating from approximately 7,000 square feet at One Grand Central Place to 21,401 square feet on the 49th floor of the Empire State Building.
06:57 EDTICPTIntercept added to short-term buy list at Deutsche Bank
Subscribe for More Information
April 7, 2015
19:10 EDTRGLSOn The Fly: After Hours Movers
Subscribe for More Information
16:12 EDTRGLSRegulus up 5% after RG-125 selected as clinical candidate by AstraZeneca
Subscribe for More Information
16:12 EDTRGLSRegulus RG-125 selected as clinical candidate by AstraZeneca
Regulus Therapeutics (RGLS) announced the selection of RG-12, a GalNAc-conjugated anti-miR targeting microRNA-103/107, or miR-103/107, for the treatment of Non Alcoholic Steatohepatitis, or NASH, in patients with type 2 diabetes/pre-diabetes, as a clinical candidate by AstraZeneca (AZN) under the companies' strategic alliance to discover, develop and commercialize microRNA therapeutics. RG-125 is the first compound from the alliance to be selected for clinical development by AstraZeneca. In connection with the candidate selection, AstraZeneca will pay Regulus $2.5M and will assume development of the program following acceptance of an Investigational New Drug application. In the near term, Regulus and AstraZeneca plan to submit key preclinical data on the RG-125 program to be presented at a scientific meeting later this year and expect to initiate a Phase I study of RG-125 in humans by the end of 2015.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use